Page 1 Extracted Terms:
- Myocarditis  
- Acute myocarditis  
- Cardioimmunology  
- Heart failure (moderate to severe, acute)  
- Myocardial infarction  
- Normal coronary arteries  
- Arrhythmias (including premature ventricular complexes)  
- Premature ventricular complexes (PVCs)  
- Arrhythmia monitoring  
- Cardiac damage  
- Cardiac imaging  
- Cardiovascular medicine  
- Heart failure treatment and recovery  
- Genetic testing (in myocarditis)  
- Histologic diagnosis (in myocarditis)

Page 2 Extracted Terms:
- Myocarditis  
- Inflammatory disease of the heart  
- Immune‑mediated inflammatory reaction  
- Endomyocardial biopsy (EMB)  
- Cardiac magnetic resonance (CMR) imaging  
- Scar formation  
- Malignant arrhythmias  
- Cardiac dysfunction  
- Chronic inflammatory cardiomyopathy  
- Left ventricle (LV) dysfunction  
- Immune polarization  
- Pathogenic/likely pathogenic (P/LP) variants  
- Desmosomal genes  
- Dilated cardiomyopathy genes  
- Immune tolerance  
- Immunophenotyping  
- Immunological tolerance  
- Late gadolinium enhancement (LGE)  
- Dilated cardiomyopathy (DCM)  
- Desmoplakin (DSP)  
- Human leukocyte antigen (HLA)  
- Interleukin (IL)  
- Major histocompatibility complex (MHC)  
- Mus musculus microRNA (Mmu‑miR)  
- Myosin heavy chain 6 (MYH6)  
- Plakophilin‑2 (PKP2)  
- Premature ventricular complexes (PVC)  
- T‑helper lymphocyte (Th)  
- Cardiac troponin I (TNNI3)  
- Tumor necrosis factor (TNF)  
- Ventricular arrhythmias (VA)

Page 3 Extracted Terms:
**Heart disease–related terms extracted from the text**

- Myocarditis  
- Acute myocarditis  
- Chronic myocarditis  
- Definite myocarditis  
- Fulminant myocarditis  
- Nonfulminant myocarditis  
- Chest pain  
- Dyspnea  
- Heart failure  
- Syncope  
- Arrhythmia (general)  
- Ventricular arrhythmias (VAs)  
- Premature ventricular contractions (PVCs)  
- Myocardial infarction with normal coronary arteries  
- Cardiac magnetic resonance imaging (CMR)  
- Fluorodeoxyglucose positron emission tomography (FDG‑PET)  
- Non‑ischemic cardiomyopathy  
- Ventricular arrhythmia (VA) ablation  
- Third‑degree atrioventricular (AV) block  
- Sarcoidosis (cardiac form)  
- Giant‑cell myocarditis  
- Lyme carditis  
- Endomyocardial biopsy (EMB)  
- Immunosuppressive therapy (e.g., for sarcoidosis, eosinophilic, giant‑cell myocarditis)  
- Immune checkpoint inhibitors (treatment implications)  
- Antibiotics (for Lyme carditis)  
- Genetic screening  
- Genetic counseling  
- Cascade screening  
- Histopathologic criteria (Dallas criteria)  
- Clinicopathologic criteria (Lieberman criteria)  
- Inflammatory infiltrate classification  
- Cardiac viral infiltrate (viral‑positive / viral‑negative)  
- Viral tropism  
- Duration of symptoms (acute vs chronic)  
- Severity of presentation (fulminant vs nonfulminant)  
- Extracellular volume (ECV)  
- Ribonucleic acid (RNA)  
- Cardiovascular diagnostic tests (e.g., CMR before device implantation)  
- Competitive sports restriction  

This list captures the key heart‑disease concepts, conditions, diagnostics, treatments, and classification terms mentioned in the excerpt.

Page 4 Extracted Terms:
- Myocarditis  
- Probable myocarditis  
- Definite myocarditis  
- Unexplored myocarditis  
- Fulminant myocarditis  
- Cardiogenic shock  
- Endomyocardial biopsy (EMB)  
- Cardiac magnetic resonance imaging (CMR)  
- Myocardial infarction with nonobstructive coronary arteries (MINOCA)  
- Nonischemic cardiomyopathy (NICMP)  
- Premature ventricular complexes (PVC)  
- Ventricular tachycardia (VT)  
- Heart failure  
- Cardiac imaging  
- Electrophysiology  
- Interventional cardiology

Page 5 Extracted Terms:
- Myocarditis  
- Giant cell myocarditis  
- Cardiac sarcoidosis  
- Eosinophilic myocarditis  
- Lymphocytic myocarditis  
- Viral myocarditis  
- Cardiogenic shock  
- Ventricular tachycardia (VT)  
- Third‑degree atrioventricular block  
- Ventricular arrhythmia (VA)  
- Supraventricular arrhythmias  
- Heart failure  
- Restrictive cardiomyopathy  
- Dilated cardiomyopathy  
- Left ventricle (LV)  
- Right ventricle (RV)  
- Left ventricular ejection fraction (LVEF)  
- Late gadolinium enhancement (LGE)  
- Cardiac magnetic resonance (CMR)  
- Endomyocardial biopsy (EMB)  
- Endocardial voltage mapping (EVM)  
- Flurodeoxyglucose positron emission tomography (FDG‑PET)  
- Guideline‑directed medical therapy (GDMT)  
- Implantable cardioverter‑defibrillator (ICD)  
- Cardiovascular implantable electronic device (CIED)  
- Mechanical circulatory support (MCS)  
- Inotropes  
- Multidrug immunosuppression  
- Corticosteroids (steroids)  
- Methotrexate (MTX)  
- Cyclophosphamide  
- Imatinib  
- Transplant evaluation  
- Lake Louise criteria (CMR findings)  
- ACE2‑tropic, cardiotropic, vasculotropic, lymphotropic, cardiotoxic (viral tropism mechanisms)  
- Adenovirus, enteroviruses, Parvovirus B19, CMV, EBV, HHV‑6, HCV, HIV, influenza, MERS‑CoV, SARS‑CoV, SARS‑CoV‑2 (viruses implicated in viral myocarditis)  
- Granulomas  
- Multinucleated giant cells  
- Eosinophils  
- Histiocytes  
- Myocyte necrosis  
- Embolization of thrombi  
- Restrictive valve involvement  

These terms capture the primary diseases, clinical manifestations, diagnostic tools, imaging findings, therapeutic strategies, and virus-related aspects relevant to heart disease as described in the text.

Page 6 Extracted Terms:
- Myocarditis  
- Acute myocarditis  
- Fulminant myocarditis  
- Complicated myocarditis  
- Uncomplicated myocarditis  
- Myocardial infarction  
- Heart disease (general term)  
- Cardiac mortality  
- Heart transplantation  
- Left ventricular ejection fraction (LVEF)  
- LVEF < 50%  
- Left ventricular (LV) dysfunction  
- Left bundle branch block (LBBB)  
- Ventricular arrhythmia  
- Atrioventricular (AV) block  
- Conduction abnormalities  
- Electrocardiographic (ECG) changes  
- Diffuse ST‑segment elevation  
- T‑wave abnormalities  
- QRS prolongation (>120 ms)  
- Q‑waves  
- PVCs (premature ventricular complexes)  
- Polymorphic PVCs  
- Syncope  
- Chest pain  
- Dyspnea / shortness of breath  
- Heart failure symptoms  
- Pericardial effusion / fluid  
- LV dilatation  
- LV hypertrophy  
- Diastolic dysfunction  
- Global longitudinal strain (GLS)  
- Erythrocyte sedimentation rate (ESR)  
- C‑reactive protein (CRP)  
- Cardiac troponin T (cTnT)  
- Natriuretic peptides (BNP/NT‑proBNP)  
- Viral titers  
- MicroRNAs (e.g., mmu‑miR‑721)  
- Th‑17 immune response  
- Immune polarization  
- Autoimmune / autoinflammatory conditions  
- Sarcoidosis  
- Lyme carditis  
- COVID‑19 myocarditis / vaccine‑related myocarditis  
- Inflammatory cardiomyopathy (chronic)  
- Chronic inflammatory cardiomyopathy  
- Immunosuppressive therapies  
- Intensive care unit (ICU) monitoring  
- Stratified diagnostic tiers (acute evaluation, definitive confirmation, auxiliary diagnostics)

Page 7 Extracted Terms:
- Myocarditis  
- Uncomplicated myocarditis  
- High‑risk features (e.g., ventricular arrhythmias, atrioventricular conduction abnormalities)  
- Telemetry capability  
- Ventricular arrhythmias  
- Atrioventricular conduction abnormalities  
- Troponin elevation  
- ST‑segment abnormalities  
- T‑wave abnormalities  
- Chest pain  
- Regional wall motion abnormalities  
- Coronary artery disease  
- Coronary angiogram  
- Myocardial injury  
- Th17 immune response  
- MicroRNAs (mmu‑miR‑721)  
- Endomyocardial biopsy (EMB)  
- Cardiac magnetic resonance imaging (CMR)  
- Cardiac magnetic resonance imaging (CMR)  
- Endomyocardial voltage mapping (EVM)  
- Intensive care unit (ICU)  
- Left ventricle (LV)  
- Left ventricular ejection fraction (LVEF)  
- Mechanical circulatory support (MCS)  
- New York Heart Association Class (NYHA)  
- Ventricular arrhythmia (VA)  
- Telemetry unit  
- Ambulatory management  
- Acute diagnostic evaluation  
- Confirmatory diagnostic evaluation  
- Tier‑2 diagnosis of definite myocarditis  
- Cardiac inflammation  
- Inflammatory infiltrate (on EMB)  
- Prognostic information (from EMB)  
- Emergency department (ED)

Page 8 Extracted Terms:
**Key heart‑disease related terms extracted from the text**

- Myocarditis  
- Giant cell myocarditis  
- Eosinophilic myocarditis  
- Cardiac sarcoidosis  
- Lymphocytic myocarditis  
- Endomyocardial biopsy (EMB)  
- Cardiac magnetic resonance imaging (CMR)  
- 3‑D spatial immunophenotyping  
- Laser capture microdissection  
- Gene expression profiling  
- Single‑cell RNA sequencing  
- Desmoplakin mutation  
- New York Heart Association (NYHA) Class ≥ III/IV  
- High‑sensitive cardiac troponin T (cTnT)  
- Creatine kinase MB (CK‑MB)  
- Creatine kinase MM (CK‑MM)  
- Soluble interleukin‑1 receptor‑like 1 (ST2)  
- N‑terminal pro‑B‑type natriuretic peptide (NT‑proBNP)  
- C‑reactive protein (CRP)  
- Erythrocyte sedimentation rate (ESR)  
- White blood cell (WBC) count with differential  
- Eosinophil count  
- Autoantibodies:  
  - Antinuclear antibody (ANA)  
  - Anti‑double‑stranded DNA (anti‑dsDNA)  
  - Cardi‑olipin IgG/IgM  
  - Antineutrophil cytoplasmic antibody (ANCA)  
  - Myeloperoxidase (MPO)  
  - Proteinase‑3 (PR‑3)  
  - Anti‑cyclic citrullinated peptide (anti‑CCP)  
  - Anti‑SSA (Ro)  
  - Anti‑SSB (La)  
  - Anti‑Scl‑70  
  - Anti‑RNA polymerase III  
- Viral serology: HCV, HIV, Lyme borreliosis, influenza  
- Medications associated with myocarditis:  
  - Cephalosporins  
  - Digoxin  
  - Diuretics  
  - Dobutamine  
  - Sulfonamides  
  - Tricyclic antidepressants  
- Substance exposures: cocaine, amphetamines, ethanol, copper, iron, lead, venomous bites  
- SARS‑CoV‑2 infection and mRNA vaccination  
- Immune checkpoint inhibitors  
- Anthracyclines  
- Interleukin‑2 receptor (soluble IL‑2R)  
- Clinical parameters: coronary syndromes, arrhythmia/syncope, chest pain, dyspnea  
  
These terms capture the core clinical, diagnostic, laboratory, and therapeutic concepts relevant to heart disease as presented in the excerpt.

Page 9 Extracted Terms:
- Myocarditis  
- Acute myocarditis  
- Cardiac magnetic resonance imaging (CMR)  
- Endomyocardial biopsy (EMB)  
- Myocardial edema  
- T1‑based imaging (T1‑mapping)  
- T2‑based imaging (T2‑mapping)  
- Lake Louise criteria (2009 & 2018)  
- Myocardial infarction with normal coronary arteries  
- Arrhythmia  
- Extracellular volume (ECV)  
- Late gadolinium enhancement (LGE)  
- LGE mid‑wall localization  
- Left ventricular ejection fraction (LVEF) < 50%  
- Cardiac sarcoidosis  
- Cardiac ischemia  
- Perfusion CMR  
- Immune checkpoint inhibitors (ICI)  
- Flurodeoxyglucose positron emission tomography (FDG‑PET)  
- PCR (polymerase chain reaction) as a diagnostic tool in myocarditis  
- Optimal medical therapy (OMT)  
- Endocardial voltage mapping (EVM)

Page 10 Extracted Terms:
- Myocarditis  
- Suspected myocarditis diagnostic criteria  
- Classical myocarditis features  
- Cardiac magnetic resonance imaging (CMR)  
- Endomyocardial biopsy (EMB)  
- FDG‑PET (fluorodeoxyglucose positron emission tomography)  
- Persistent inflammation in myocarditis  
- Autoimmune conditions associated with myocarditis  
- P/LP genetic variants (predisposing pathogenic/likely pathogenic variants)  
- Cardiomyopathy unresponsive to standard medical therapy (>3 months)  
- Hemodynamic stability  
- Ventricular arrhythmia (VA)  
- Atrioventricular conduction abnormalities  
- Cardiac troponin normalization  
- Exercise testing restriction in acute myocarditis  
- Low‑risk features for myocarditis  
- High‑risk features for myocarditis  
- Left ventricular (LV) dysfunction  
- LV ejection fraction (LVEF)  
- Myocardial infarction with normal coronary arteries  
- Heart failure  
- Transplant in myocarditis  
- LGE (late gadolinium enhancement) on CMR  
- LGE persistence/reciprocal changes (increase, decrease, resolution)  
- LGE without edema (predictor of adverse events)  
- Cardiac sarcoidosis  
- STREAM study (FDG‑PET/CT vs. MRI/EMB)  
- Monomorphic ventricular tachycardia (VT)  
- Polymorphic ventricular tachycardia (VT)  
- Scar‑related VT  
- Voltage mapping (bipolar endocardial voltage mapping)  
- Immunosuppressive therapy in myocarditis  
- Implantable cardioverter‑defibrillator (ICD) implantation  
- Holter monitoring  
- 12‑lead ECG assessment  
- Follow‑up imaging in myocarditis  
- Follow‑up arrhythmia monitoring  
- Follow‑up exercise testing restriction  
- Genetic counseling and cascade screening in myocarditis  
- Chronic inflammatory cardiomyopathy  
- Giant cell myocarditis  
- Inflammatory infiltrate risk for VAs  
- Mid‑wall LGE  
- LVEF on initial CMR  
- LGE extent and location  
- Scar re‑entry circuits  
- Inflammation‑induced ion channel dysfunction  
- Altered intracellular signaling in myocardial inflammation  
- Cardiogenic risk stratification in myocarditis  
- Follow‑up interval recommendations (e.g., 3‑month CMR, 196‑day imaging)  
- Registries: Lombardy registry, ITAMY (Italian Study in Myocarditis)  
- Mortality and transplant event rates in complicated vs. fulminant myocarditis.

Page 11 Extracted Terms:
**Heart disease–related terms extracted from the text**

- Suspected myocarditis  
- Myocarditis  
- Arrhythmogenic cardiomyopathy (ACM)  
- Arrhythmogenic right ventricular cardiomyopathy (ARVC)  
- Sudden death in young athletes  
- High‑risk features (in myocarditis)  
- Clinical‑relevant arrhythmias  
- Ventricular arrhythmias (frequent or complex repetitive forms)  
- Supraventricular arrhythmias (frequent or complex repetitive forms)  
- Exercise testing (acute phase & follow‑up)  
- European Association of Preventive Cardiology (position paper)  
- Periodical reassessment (first 2 years and yearly thereafter)  
- LGE present (late gadolinium enhancement)  
- ARVC (arrhythmogenic right ventricular cardiomyopathy)  
- CMR – cardiac magnetic resonance  
- CS – cardiac sarcoidosis  
- EVM – endocardial voltage mapping  
- FDG‑PET – flurodeoxyglucose positron emission tomography  
- FU – follow‑up  
- GCM – giant cell myocarditis  
- GDMT – guideline‑directed medical therapy  
- HF – heart failure  
- HTX – heart transplant  
- ICD – implantable cardioverter‑defibrillator  
- LBBB – left bundle branch block  
- LGE – late gadolinium enhancement  
- LVAD – left ventricular assist device  
- LVSD – left ventricular systolic dysfunction  
- NYHA – New York Heart Association Class  

These are the key heart‑disease–related terms and abbreviations cited in the provided excerpt.

Page 12 Extracted Terms:
- Myocarditis  
- Left ventricular ejection fraction (LVEF)  
- Myocardial injury biomarkers  
- Holter monitoring  
- Exercise testing  
- Human leukocyte antigen haplotypes  
- P/LP (pathogenic/likely pathogenic) variants  
- TTN (titin) variants  
- Desmoplakin (DSP) variants  
- Arrhythmogenic cardiomyopathy  
- Canonical Wnt–β‑catenin signaling  
- Th2 immune polarization  
- Cardiomyopathy (including dilated and familial forms)  
- Genetic testing (at time of new cardiomyopathy diagnosis)  
- Genetic screening for myocarditis patients  
- Genetic counseling (including pre‑implantation counseling)  
- Cascade screening  
- Competitive sports prohibition  
- Implantable cardioverter‑defibrillator (ICD) implantation  
- Heart failure  
- Arrhythmia  
- Persistent inflammation  
- Cardiac magnetic resonance (CMR) imaging  
- Immune phenotyping  
- Giant cell myocarditis  
- Pulmonary sarcoidosis (cardiac involvement)

Page 13 Extracted Terms:
- Myocarditis  
- Cardiomyopathy  
- Heart failure  
- Ventricular arrhythmia  
- Ventricular tachycardia  
- Non‑obstructive coronary arteries  
- Myocardial infarction  
- Cardiac magnetic resonance imaging (CMR)  
- Late gadolinium enhancement  
- T1 mapping  
- T2 mapping  
- Endomyocardial biopsy  
- Immune checkpoint blockade  
- MicroRNA  
- Parvovirus B19 infection  
- Cardiac sarcoidosis  
- Idiopathic giant cell myocarditis  
- Positron emission tomography (PET)  
- Exercise‑induced myocarditis  
- Desmoplakin gene truncating variant  
- Risk stratification  
- Immunosuppressive therapy  
- Competitive athlete participation  
- Pericarditis  
- Non‑ischemic myocardial inflammation  
- Inflammatory cardiomyopathy  
- Aetiology of myocarditis  
- Diagnostic criteria  
- Management strategies  
- Therapeutic recommendations  

Page 14 Extracted Terms:
**Key heart‑disease related terms found in the text**

- Myocarditis  
- Autoimmune myocarditis  
- Viral myocarditis (coxsackievirus B3‑induced, viral myocarditis)  
- Desmoplakin cardiomyopathy  
- Arrhythmogenic cardiomyopathy  
- Dilated cardiomyopathy  
- Heart failure  
- Cardiac fibrosis  
- Cardiac remodeling  
- Cardiac hypertrophy  
- Cardiac injury  
- Cardiac magnetic resonance imaging (CMR)  
- Cardiac myosin (S2 region, alpha‑myosin)  
- T cell‑mediated inflammation  
- Regulatory T cells (Treg)  
- Th17 cells  
- Th2 cells  
- CD4⁺ T cells  
- CD69 (exhaustion marker)  
- Interleukin‑17 (IL‑17)  
- Interleukin‑4 (IL‑4)  
- Interleukin‑37 (IL‑37)  
- Bcl2‑like protein 12 (BCL2L12)  
- STAT6 (signal transducer and activator of transcription 6)  
- PKCβ (protein kinase C beta)  
- ERK1/2 (extracellular signal‑regulated kinases 1/2)  
- NF‑κB (nuclear factor kappa‑B)  
- Toll‑like receptors (TLRs)  
- Human leukocyte antigen class II (HLA‑II) associations  
- MicroRNA‑155 (miR‑155)  
- MicroRNA‑21 (miR‑21)  
- Antigen‑presenting cells (APCs)  
- I‑Aκ (MHC II molecule on APCs)  
- Cardiomyopathy (general term)  
- Heart transplant rejection  
- Tissue‑based molecular diagnostic system (MMDx)  
- Autoimmunity (in the context of cardiovascular disease)  
- Gene‑expression profiling (for cardiac disease)  

These terms capture the central diseases, cellular mechanisms, cytokines, and molecular markers relevant to heart disease as highlighted in the provided references.

